Charles River has entered into an exclusive licensing agreement with Crown Bioscience to breed and distribute their Zucker Diabetic Sprague-Dawley (ZDSD) rat model.
Charles River’s commercial distribution of the ZDSD model is expected to begin by mid-summer 2019. To be among the first to be alerted, register now to receive advanced notification prior to the commercial launch.
The ZDSD rat is a highly translatable rodent model of metabolic syndrome, obesity, dyslipidemia, and diabetes with complications such as cardiac dysfunction, proteinuria, and impaired wound healing. It has a polygenic background and intact leptin pathway. The ZDSD rat more closely mimics human disease development. Unlike some other rat models of metabolic disease, it does not rely on monogenic leptin or leptin receptor mutations for development of obesity and Type 2 diabetes.
See related models: